| ²é¿´: 519 | »Ø¸´: 1 | |||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | |||
СÍèÍè9Ìú³æ (ÕýʽдÊÖ)
|
[ÇóÖú]
Çó·ÒëÒ»¾ä»°£¬Ð»Ð»
|
||
|
The studies are being conducted in a patient population at risk for CV clinical events. Primary endpoints are clinical endpoints or prevention of arrhythmias in post-MI patients; Tg-lowering is not an efficacy measure |
» ²ÂÄãϲ»¶
302Çóµ÷¼ÁÒ»Ö¾Ô¸»ªÖÐʦ·¶´óѧ
ÒѾÓÐ8È˻ظ´
338Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
»¯Ñ§µ÷¼Á
ÒѾÓÐ12È˻ظ´
342Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
0835ѧ˶299Çóµ÷¼Á 08´óÀà¿É½ÓÊÜ
ÒѾÓÐ4È˻ظ´
085602µ÷¼Á ³õÊÔ×Ü·Ö335
ÒѾÓÐ3È˻ظ´
288»·¾³×¨Ë¶,Çóµ÷²ÄÁÏ·½Ïò
ÒѾÓÐ5È˻ظ´
É격
ÒѾÓÐ5È˻ظ´
081200-11408-276ѧ˶Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
085600µ÷¼Á
ÒѾÓÐ4È˻ظ´

ssssllllnnnn
ÖÁ×ðľ³æ (ÖªÃû×÷¼Ò)
Translator and Proofreader
- ·ÒëEPI: 1690
- Ó¦Öú: 452 (˶ʿ)
- ½ð±Ò: 31580.9
- ºì»¨: 100
- Ìû×Ó: 7681
- ÔÚÏß: 19966.6Сʱ
- ³æºÅ: 3328089
- ×¢²á: 2014-07-17
- רҵ: Ö×Áö·¢Éú
2Â¥2015-08-24 11:34:49














»Ø¸´´ËÂ¥